A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: Application to a clinical pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 926, Issue , 2013, Pages 36-41

  Furlong, Michael T ^a   Savant, Ishani ^a   Yuan, Moucun ^b   Scott, Laura ^b   Mylott, William ^b   Mariannino, Thomas ^b   Kadiyala, Pathanjali ^a   Roongta, Vikram ^c   Arnold, Mark E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Pharmaceutical Product Development   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Assay; Clopidogrel; Derivatization; HPLC MS MS; Pharmacokinetics; Thiol metabolite

Indexed keywords

CHROMATOGRAPHIC CONDITIONS; CHROMATOGRAPHIC SEPARATIONS; CLOPIDOGREL; DERIVATIZATIONS; HPLC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; PERIPHERAL ARTERIAL DISEASE; POSITIVE ION ELECTROSPRAY TANDEM MASS SPECTROMETRIES;

ASSAYS; CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPES; MASS SPECTROMETRY; METABOLITES; ORGANIC SOLVENTS; PHARMACOKINETICS; PLASMA (HUMAN); QUALITY CONTROL;

BIOMOLECULES;

2 BROMO 3' METHOXYACETOPHENONE; ACETOPHENONE DERIVATIVE; CLOPIDOGREL; DRUG METABOLITE; THIOL; UNCLASSIFIED DRUG;

ACCURACY; ALKYLATION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTEREOISOMER; DRUG BLOOD LEVEL; DRUG STABILITY; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; LOADING DRUG DOSE; MASS SPECTROMETRY; NORMAL HUMAN; POSITIVE ION ELECTROSPRAY; PRECIPITATION; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; ROOM TEMPERATURE; SINGLE DRUG DOSE; THAWING; VALIDATION STUDY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; PLATELET AGGREGATION INHIBITORS; TANDEM MASS SPECTROMETRY; TICLOPIDINE;

EID: 84877812890     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.02.031     Document Type: Article

References (16)

1. Sanofi-aventis/Bristol-Myers Squibb. Plavix® (clopidogrel bisulfate) prescribing information (2011).
2. Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., Pascal M., Herbert J.M. Thromb. Haemost. 2000, 84:891.
3. Pereillo J.-M., Maftouh M., Andrieu A., Uzabiaga M.-F., Fedeli O., Savi P., Pascal M., Herbert J.-M., Maffrand J.-P., Picard C. Drug Metab. Dispos. 2002, 30:1288.
4. Tuffal G., Roy S., Lavisse M., Brasseur D., Schofield J., Touchard N.D., Savi P., Bremond N., Rouchon M.-C., Hurbin F., Sultan E. Thromb. Haemost. 2011, 105:696.
5. Abell L.M., Liu E.C.K. J. Pharmacol. Exp. Ther. 2011, 339:589.
6. Simon T., Bhatt D.L., Bergougnan L., Farenc C., Pearson K., Perrin L., Vicaut E., LaCreta F., Hurbin F., Dubar M. Clin. Pharmacol. 2011, 90:287.
7. Judge H.M., Patil S.B., Buckland R.J., Jakubowski J.A., Storey R.F. J Thromb. Haemostasis 2010, 8:1820.
8. Angiolillo D.J., Gibson C.M., Cheng S., Ollier C., Nicolas O., Bergougnan L., Perrin L., LaCreta F.P., Hurbin F., Dubar M. Clin. Pharmacol. Therap. 2011, 89:65.
9. Taubert D., Kastrati A., Harlfinger S., Gorchakova O., Lazar A., von Beckerath N., Schoemig A., Schoemig E. Thromb. Haemost. 2004, 92:311.
10. Takahashi M., Pang H., Kawabata K., Farid N.A., Kurihara A. J. Pharm. Biomed. Anal. 2008, 48:1219.
11. Delavenne X., Basset T., Zufferey P., Malouk N., Laporte S., Mismetti P. J. Sep. Sci. 2010, 33:1968.
12. Peer C.J., Spencer S.D., Van Den Berg D.A.H., Pacanowski M.A., Horenstein R.B., Figg W.D. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2012, 880:132.
13. FDA Guidance for Industry. Bioanalytical Method Validation, (2001).
14. Fu I., Woolf E.J., Matuszewski B.K. J. Pharm. Biomed. Anal. 1998, 18:347.
15. Stokvis E., Rosing H., Beijnen J.H. Rapid Commun. Mass Spectrom. 2005, 19:401.
16. Fast D.M., Kelley M., Viswanathan C.T., O'Shaughnessy J., King S.P., Chaudhary A., Weiner R., DeStefano Anthony J., Tang D. AAPS J. 2009, 11:238.